Arkolith/Insider Trading/NAMS/Form 4

Kooij Louise Frederika

Chief Accounting OfficerNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Jan 29, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.3M
Net Open-Market Flow
-$2.3M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 28, 2026Option exercise(M)33K$10.90$355K57K
Jan 28, 2026Sell(S)33K$31.80$1.0M24K
Jan 27, 2026Sell(S)40K$32.62$1.3M24K
Jan 27, 2026Option exercise(M)40K$10.90$434K64K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 28, 2026Option exercise(M)33K—$073K
Jan 27, 2026Option exercise(M)40K—$0106K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-029526) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML